Cutaneous Squamous Cell Carcinoma

The FDA granted priority review to cemiplimab-rwlc for treatment of certain patients with non-small cell lung cancer.

Pembrolizumab monotherapy appeared to be effective and safe as first-line treatment for patients with unresectable cutaneous squamous cell carcinoma, according to results of a phase 2 study published in Journal of Clinical Oncology.

Patients with cutaneous squamous cell carcinoma with perineural invasion who underwent adjuvant radiotherapy in addition to Mohs micrographic surgery experienced improved outcomes compared with patients who underwent surgery alone.

The FDA approved pembrolizumab for treatment of recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

Lung transplant recipients who were treated with voriconazole to prevent aspergillosis were significantly more likely than those who did not receive voriconazole to develop squamous cell carcinoma, according to a study.

A predominance of host-associated risk factors compared with transplant-associated risk factors has been identified in association with the development of keratinocyte carcinoma after allogeneic hematopoietic cell transplant, according to a study published in JAMA Dermatology.

American Society for Radiation Oncology has issued guidelines on the use of radiation therapy in the management of basal and cutaneous squamous cell carcinomas.

In the most popular Healio Dermatology story last week, Suzanne Bruce, MD, presented findings at the American Society for Dermatologic Surgery annual meeting from her research weighing the positives and negatives of private equity to help her decide how to transition her dermatology practice to allow more time with her family.

CHICAGO — In patients with advanced cutaneous squamous cell carcinoma, a multidisciplinary discussion on treatment options should include oncologists, radiation oncologists and the primary care physician in weighing risks and benefits to various approaches, according to Todd Schlesinger, MD, FAAD, FASMS, medical director at Dermatology and Laser Center of Charleston.

The use of salvage limited-field irradiation in aggressive cutaneous squamous cell carcinoma with microscopic residual disease resulted in a progression rate of more than 80%, which is much higher than the usual failure rate for high-risk cutaneous squamous cell carcinoma, according to findings published in JAMA Dermatology.